Acamprosate calcium

Names

[ Name ]:
Acamprosate calcium

[Synonym ]:
Campral
Acamprosate calcium
MFCD00886588
calcium acetylhomotaurinate
Calciumbis[3-(acetylamino)propan-1-sulfonat]
CA-Aota
Alcomed
3-(Acetylamino)-1-propanesulfonic Acid Calcium Salt (2:1)
Sobriol
1-Propanesulfonic acid, 3-(acetylamino)-, calcium salt (2:1)
Calcium bis(3-acetamido-1-propanesulfonate)
Calcium Bisacetyl Homotaurine
bis[3-(acétylamino)propane-1-sulfonate] de calcium
Aotal
calcium acetyl homotaurinate
calcium bis[3-(acetylamino)propane-1-sulfonate]
calcium,3-acetamidopropane-1-sulfonate
EINECS 278-665-3
Calcium bis(3-acetamidopropane-1-sulfonate)
Acamprosate (calcium)

Biological Activity

[Description]:

Acamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction.IC50 value:Target: GABA receptorAcamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence.Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol.

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor

Signaling Pathways >> Neuronal Signaling >> GABA Receptor

Research Areas >> Neurological Disease

[References]

[1]. Preuss UW. Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.).Alcohol Clin Exp Res. 2012 Jun;36(6):967-9. doi: 10.1111/j.1530-0277.2012.01827.x.

[2]. Witkiewitz K, Saville K, Hamreus K.Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility.Ther Clin Risk Manag. 2012;8:45-53.

[3]. Gahr M, et al. Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy.Nervenarzt. 2012 Aug 15.

[4]. Palucha-Poniewiera A, Pilc A.Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6.

[5]. Hinton DJ, et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1.Neuropharmacology. 2012 Jun;62(8):2480-8.

[Related Small Molecules]

Chemical & Physical Properties

[ Melting Point ]:
>300ºC

[ Molecular Formula ]:
C₅H₁₀NO₄S_.1/₂Ca

[ Molecular Weight ]:
200.24

[ PSA ]:
189.36000

[ LogP ]:
1.05900

[ Storage condition ]:
Room temp

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
26-36/37/39-36

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2924199090

Customs

[ HS Code ]: 2924199090

[ Summary ]:
2924199090. other acyclic amides (including acyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Articles

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.

Sci. Rep. 5 , 7608, (2015)

Alzheimer disease (AD) represents a major medical problem where mono-therapeutic interventions demonstrated only a limited efficacy so far. We explored the possibility of developing a combinational th...

Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.

Neuropsychopharmacology 39(11) , 2601-10, (2014)

Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has been extensively investigated as a promising target to treat alcoholism. Encouraging results obtained with the endogenou...

Acamprosate calcium as augmentation therapy for anxiety disorders.

Ann. Pharmacother. 44 , 1930-2, (2010)

Glutamate is a major excitatory neurotransmitter, while γ-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought ...